The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Resolvedstocks

Immutep Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma Treatment

First Detected: Apr 16, 2026, 4:17 AM

Last Update: 3 months ago

5 articles·4 stories

Event Summary

On April 16, the US FDA granted Orphan Drug Designation to eftilagimod alfa for the treatment of Soft Tissue Sarcoma (STS). This drug targets a rare cancer with significant unmet medical needs.

Timeline

FDA Lifts Partial Clinical Hold on MacroGenics Cancer Study

Apr 16, 2026, 10:18 PMImpact: 7

Cellectar Biosciences Enrolls First Patient in Phase 1b Trial for CLR 125 Breast Cancer Treatment

Apr 16, 2026, 9:17 AMImpact: 5

FDA Grants Fast Track Designation to Climb Bio’s Treatment for Rare Kidney Disease

Apr 16, 2026, 4:30 AMImpact: 6

Immutep Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma Treatment

Apr 16, 2026, 4:17 AMImpact: 7

Immutep Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma Treatment

Event Summary

Timeline

Price Impact